Peter Gimsing

9.0k total citations
111 papers, 3.1k citations indexed

About

Peter Gimsing is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Peter Gimsing has authored 111 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 88 papers in Hematology, 62 papers in Molecular Biology and 47 papers in Oncology. Recurrent topics in Peter Gimsing's work include Multiple Myeloma Research and Treatments (81 papers), Protein Degradation and Inhibitors (25 papers) and Cancer Treatment and Pharmacology (23 papers). Peter Gimsing is often cited by papers focused on Multiple Myeloma Research and Treatments (81 papers), Protein Degradation and Inhibitors (25 papers) and Cancer Treatment and Pharmacology (23 papers). Peter Gimsing collaborates with scholars based in Denmark, Sweden and Norway. Peter Gimsing's co-authors include Lene Meldgaard Knudsen, Annette Juul Vangsted, Ingemar Turesson, Konstantinos Dimopoulos, Erik Hippe, Kirsten Grønbæk, Niels Abildgaard, Tobias Wirenfeldt Klausen, Hans Erik Johnsen and Ebba Nexø and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Peter Gimsing

110 papers receiving 3.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Peter Gimsing Denmark	31	2.1k	1.9k	1.4k	324	301	111	3.1k
Tibor Kovacsovics United States	29	2.3k 1.1×	1.4k 0.7×	880 0.6×	433 1.3×	639 2.1×	123	3.7k
Niklas Zojer Austria	26	1.8k 0.9×	1.7k 0.9×	1.1k 0.8×	263 0.8×	474 1.6×	125	2.7k
Ellin Berman United States	31	2.2k 1.1×	1.2k 0.7×	1.2k 0.9×	423 1.3×	992 3.3×	99	3.8k
Kazuyuki Shimizu Japan	17	2.6k 1.2×	1.7k 0.9×	1.8k 1.3×	282 0.9×	456 1.5×	67	3.5k
H M Lokhorst Netherlands	35	2.3k 1.1×	1.7k 0.9×	1.5k 1.1×	583 1.8×	402 1.3×	80	3.6k
Donna M. Weber United States	28	2.7k 1.3×	2.4k 1.3×	1.6k 1.1×	251 0.8×	616 2.0×	132	3.6k
Antonio Palumbo Italy	34	3.5k 1.7×	2.6k 1.4×	2.0k 1.4×	286 0.9×	485 1.6×	131	4.0k
Robert A. Kyle United States	27	1.1k 0.5×	1.4k 0.8×	586 0.4×	141 0.4×	409 1.4×	45	2.2k
Merav Leiba Israel	23	929 0.4×	824 0.4×	930 0.7×	586 1.8×	224 0.7×	77	2.0k
Edward N. Libby United States	22	1.2k 0.6×	1.1k 0.6×	1.1k 0.8×	224 0.7×	268 0.9×	87	2.5k

Countries citing papers authored by Peter Gimsing

Since Specialization

Citations

This map shows the geographic impact of Peter Gimsing's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Gimsing with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Gimsing more than expected).

Fields of papers citing papers by Peter Gimsing

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Gimsing. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Gimsing. The network helps show where Peter Gimsing may publish in the future.

Co-authorship network of co-authors of Peter Gimsing

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Gimsing. A scholar is included among the top collaborators of Peter Gimsing based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Gimsing. Peter Gimsing is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Klausen, Tobias Wirenfeldt, Annette Juul Vangsted, Henrik Gregersen, et al.. (2020). Validation of the UK myeloma research alliance risk profile, a new clinical prediction model for outcome in patients with newly diagnosed multiple myeloma not eligible for autologous stem cell transplantation; a population‐based study from the Danish national multiple myeloma registry. British Journal of Haematology. 193(1). 119–124. 14 indexed citations

Sørrig, Rasmus, Tobias Wirenfeldt Klausen, Birgitte Preiss, et al.. (2018). Early relapsed disease of multiple myeloma following up-front HDM-ASCT: a study based on the Danish Multiple Myeloma Registry in the period 2005 to 2014. Leukemia. 32(9). 2054–2057. 7 indexed citations

Klausen, Tobias Wirenfeldt, Henrik Gregersen, Niels Abildgaard, et al.. (2018). The majority of newly diagnosed myeloma patients do not fulfill the inclusion criteria in clinical phase III trials. Leukemia. 33(2). 546–549. 31 indexed citations

Dimopoulos, Konstantinos, Christian Winther Eskelund, Lene Dissing Sjø, et al.. (2018). Expression of CRBN, IKZF1, and IKZF3 does not predict lenalidomide sensitivity and mutations in the cereblon pathway are infrequent in multiple myeloma. Leukemia & lymphoma. 60(1). 180–188. 20 indexed citations

Vangsted, Annette Juul, Jack B. Cowland, Peter Buhl Jensen, et al.. (2017). Drug response prediction in high-risk multiple myeloma. Gene. 644. 80–86. 12 indexed citations

Sørrig, Rasmus, Tobias Wirenfeldt Klausen, Morten Salomo, et al.. (2017). Immunoparesis in newly diagnosed Multiple Myeloma patients: Effects on overall survival and progression free survival in the Danish population. PLoS ONE. 12(12). e0188988–e0188988. 37 indexed citations

Hansson, Markus, Peter Gimsing, Ashraf Badros, et al.. (2015). A Phase I Dose-Escalation Study of Antibody BI-505 in Relapsed/Refractory Multiple Myeloma. Clinical Cancer Research. 21(12). 2730–2736. 42 indexed citations

Plesner, Torben, Hendrik‐Tobias Arkenau, Henk M. Lokhorst, et al.. (2014). Safety and efficacy of daratumumab with lenalidomide and dexamethasone in relapsed or relapsed, refractory multiple myeloma.. Journal of Clinical Oncology. 32(15_suppl). 8533–8533. 32 indexed citations

Dimopoulos, Konstantinos, Peter Gimsing, & Kirsten Grønbæk. (2013). Aberrant microRNA expression in multiple myeloma. European Journal Of Haematology. 91(2). 95–105. 41 indexed citations

10.

Hjorth, Martin, Øyvind Hjertner, Lene Meldgaard Knudsen, et al.. (2012). Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study. European Journal Of Haematology. 88(6). 485–496. 41 indexed citations

11.

Fayers, Peter, Antonio Palumbo, Cyrille Hulin, et al.. (2011). Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. Blood. 118(5). 1239–1247. 179 indexed citations

12.

Vangsted, Annette Juul, Tobias Wirenfeldt Klausen, Niels Frost Andersen, et al.. (2010). Improved survival of multiple myeloma patients with late relapse after high‐dose treatment and stem cell support, a population‐based study of 348 patients in Denmark in 1994–2004*. European Journal Of Haematology. 85(3). 209–216. 14 indexed citations

13.

Gulbrandsen, Nina, Anders Waage, Peter Gimsing, et al.. (2008). A Randomised Placebo Controlled Study With Melphalan/Prednisone Vs Melphalan/Prednisone/Thalidomide: Quality Of Life And Toxicity. Lund University Publications (Lund University). 93. 209–209. 16 indexed citations

14.

Cocks, Kim, D. Cohen, Finn Wislöff, et al.. (2007). An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma. European Journal of Cancer. 43(11). 1670–1678. 177 indexed citations

15.

Waage, Anders, Peter Gimsing, Gunnar Juliusson, Ingemar Turesson, & Peter Fayers. (2007). Melphalan-Prednisone-Thalidomide to Newly Diagnosed Patients with Multiple Myeloma: A Placebo Controlled Randomised Phase 3 Trial.. Blood. 110(11). 78–78. 32 indexed citations

16.

Waage, Anders, Peter Gimsing, Gunnar Juliusson, et al.. (2002). Low serum levels of soluble tumor necrosis factor receptors predict for response to thalidomide in advanced myeloma.. Blood. 100(11). 5082. 2 indexed citations

17.

Thunberg, Ulf, Britt Thuresson, Jan Westin, et al.. (1997). Presence of clonal cells in all stem cell enriched grafts in transplanted multiple myeloma.. Blood. 90. 218. 1 indexed citations

18.

Gimsing, Peter. (1995). Cobalamin forms and analogues in plasma and myeloid cells during chronic myelogenous leukaemia related to clinical condition. British Journal of Haematology. 89(4). 812–819. 17 indexed citations

19.

Keldsen, Nina, Ole Weis Bjerrum, Inger Marie S. Dahl, et al.. (1993). Multiple myeloma treated with mitoxantrone in combination with vincristine and prednisolone (NOP regimen) versus melphalan and prednisolone: a phase III study. European Journal Of Haematology. 51(2). 80–85. 3 indexed citations

20.

Gimsing, Peter. (1983). Determination of cobalamins in biological material. Analytical Biochemistry. 129(2). 288–295. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact